Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Immunogenicity of HIL-214 Norovirus Vaccine
NCT03039790Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2017
- Primary completion
- Jul 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 2
01
Overview
A Phase 2 trial of NoV GI.1/GII.4 bivalent VLP vaccine in norovirus gastroenteritis, sponsored by Takeda. Started Feb 2017; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus gastroenteritis
Beyond the preview
Go deeper on NCT03039790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03039790.